Skip to the main content

Original scientific paper

LAMOTRIGINE VERSUS LITHIUM AUGMENTATION OF ANTIDEPRESSANT THERAPY IN TREATMENT-RESISTANT DEPRESSION: EFFICACY AND TOLERABILITY

Maja Ivković ; Institute for Psychiatry, Clinical Center of Serbia, Belgrade, Serbia
Aleksandar Damjanović ; Institute for Psychiatry, Clinical Center of Serbia, Belgrade, Serbia
Aleksandar Jovanović ; Institute for Psychiatry, Clinical Center of Serbia, Belgrade, Serbia
Tijana Cvetić ; Institute for Psychiatry, Clinical Center of Serbia, Belgrade, Serbia
Miroslava Jašović-Gašić ; Institute for Psychiatry, Clinical Center of Serbia, Belgrade, Serbia


Full text: english pdf 246 Kb

page 187-193

downloads: 2.617

cite


Abstract

Background: Mood stabilizer augmentation of standard antidepressant drugs has been shown to be effective in treatment-resistant depression. Despite the reported high overall efficacy, lithium has been relatively underused in recent years. Lamotrigine, a novel anticonvulsant recently recognized as a mood stabilizer, seems
to have putative antidepressive properties. The aim of the study was to investigate lamotrigine efficacy and tolerability as antidepressant augmentation for unipolar treatment-resistant depression compared to lithium.
Subjects and methods: 88 patients suffering from treatment-resistant Major depressive disorder, having acute recurrent depressive episodes according to DSMIV criteria, were enrolled in the study. This was an open-label trial with a flexible dosing regimen. All patients, received antidepressants in full therapeutic doses. They were divided into two augmentation groups: 46 patients received 50-200 mg/day lamotrigine, and 42 patients received 600-1200 mg/day lithium. The
Hamilton Rating Scale for Depression (HAM-D) and The Clinical Global
Impression scale (CGI) were used to monitor therapeutic efficacy. Patients were evaluated weekly for an 8 week treatment period.
Results: The HAM-D total score was significantly reduced in both treatment groups at the study endpoint, without any difference between the groups. However, significant clinical improvement was reached within the second treatment week in the lamotrigine group compared to the lithium group (p=0.01 vs. lithium). Lamotrigine showed significant efficacy on the HAM-D item 1(depressed mood;
p=0.01), item 7 (work and interest; p=0.01) and CGI-Improvement scale (p=0.02). The drop-out rate due to treatment failure was lower in the lamotrigine group (n=1) compared to the lithium (n=4) group. Also, the incidence of side effects did not differ between the groups.
Conclusions: Our results suggest that lamotrigine could be useful as
augmentation of antidepressants for treatment-resistant unipolar depression. Also, lamotrigine may accelerate the onset of antidepressant action, and therefore might be useful in treatment of major depression in general.

Keywords

treatment; resistant depression; augmentation strategies; lamotrigine; lithium

Hrčak ID:

39682

URI

https://hrcak.srce.hr/39682

Publication date:

21.3.2009.

Visits: 3.275 *